TPG Asia Acquires Majority Stake in Taiwan-Asia Clinical CRO

TPG Capital Asia acquired a majority stake in OPC Holding Company, a Taiwan company that provides clinical trial services in China , Taiwan , South Korea and Japan . OPC has significant experience in bioequivalence trials, which may become important as China and other Asian countries require drugmakers to prove the efficacy of their generic products. OPC also operates a pan-Asian CRO unit that provides late-stage development services for novel drugs. TPG Capital Asia, a private equity investor, has $6 billion of assets under management. This size of its OPC investment was not disclosed. More details... Share this with colleagues: // //